Cardiotoxicity from chimeric antigen receptor-T cell therapy for advanced malignancies

Chimeric antigen receptor (CAR)-T cell therapy is the next revolutionary advance in cancer therapy. By using ex vivo engineered T cells to specifically target antigens, a targeted immune reaction is induced. Chimeric antigen receptor-T cell therapy is approved for patients suffering from advanced an...

Descripción completa

Detalles Bibliográficos
Autores principales: Totzeck, Matthias, Michel, Lars, Lin, Yi, Herrmann, Joerg, Rassaf, Tienush
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
State of the Art Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9123242/
https://www.ncbi.nlm.nih.gov/pubmed/35257157
http://dx.doi.org/10.1093/eurheartj/ehac106

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9123242/
https://www.ncbi.nlm.nih.gov/pubmed/35257157
http://dx.doi.org/10.1093/eurheartj/ehac106

Ejemplares similares